Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivos TherapeuticsVVOS -12.85%30 Days Sales Outstanding is 28.39 as of Jun. 2026, which is 28% above its 10-year median of 22.26. GuruFocus rates VVOS with a GF Score™ of 30/100 and a GF Value™ of $0.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Vivos Therapeutics ranks better than 91.6% on this metric.
The historical rank and industry rank for Vivos Therapeutics's Days Sales Outstanding or its related term are showing as below:
VVOS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.67 Med: 22.26 Max: 57.27
Current: 29.88
During the past 8 years, Vivos Therapeutics's highest Days Sales Outstanding was 57.27. The lowest was 7.67. And the median was 22.26.
VVOS's Days Sales Outstanding is ranked better than 91.6% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs VVOS: 29.88
Vivos Therapeutics's Days Sales Outstanding
increased
from Jun. 2025 (28.08) to Jun. 2026 (28.39).
Vivos Therapeutics (NAS:VVOS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vivos Therapeutics Days Sales Outstanding Related Terms
Vivos Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVOS vs XAIR, USAQ, STME: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Vivos Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Days Sales Outstanding falls into.
Vivos Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos Therapeutics (VVOS) has a Days Sales Outstanding of 28.39 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vivos Therapeutics and its competitors. This is 28% above median its historical median of 22.26. Over the past decade, Vivos Therapeutics' Days Sales Outstanding has ranged from 7.67 to 57.27. According to the industry distribution chart, Vivos Therapeutics ranks #68 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 8.4%.
Is Vivos Therapeutics' Days Sales Outstanding too high?
Vivos Therapeutics' current Days Sales Outstanding of 28.39 is 28% above median its 10-year median of 22.26. Over the past 10 years, this metric has ranged from a low of 7.67 to a high of 57.27. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. Vivos Therapeutics' value of 28.39 is 56.6% below this industry median. Based on the distribution chart, Vivos Therapeutics ranks #68 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Days Sales Outstanding compare to XAIR and USAQ?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #68 out of 810 companies for Days Sales Outstanding. This places Vivos Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.38. Vivos Therapeutics' value of 28.39 is 56.6% below this benchmark. Historically, Vivos Therapeutics' own Days Sales Outstanding has ranged from 7.67 to 57.27 over the past decade. While the company's 10-year median is 22.26 vs. the industry median of 65.38, Vivos Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos Therapeutics's current Days Sales Outstanding of 28.39 is 56.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Days Sales Outstanding is 28.39, which is 28% above median its own 10-year median of 22.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $0.89, compared to a current price of $0.20 — trading 78% below its estimated fair value. The current Days Sales Outstanding is 28.39, which is 28% above median its 10-year median of 22.26 and 56.6% below the Medical Devices & Instruments industry median of 65.38. Vivos Therapeutics' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Days Sales Outstanding is 28.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.20 is trading 78% below its estimated GF Value™ of $0.89.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Days Sales Outstanding: 28.39 (28% above median its 10-year median of 22.26)
GF Value™: $0.89 vs. price of $0.20 (78% below fair value)
Industry Position: 56.6% below the Medical Devices & Instruments median (#68 of 810)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
30GF Score
Get the complete analysis for VVOS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
